Prosecution Insights
Last updated: November 04, 2026
Application No. 18/751,708

SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS

Non-Final OA §112
Filed
Jun 24, 2024
Priority
Jan 10, 2020 — provisional 62/959,874 +2 more
Examiner
CHANG, KYUNG SOOK
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Topix Pharmaceuticals, Inc.
OA Round
3 (Non-Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
488 granted / 807 resolved
+0.5% vs TC avg
Strong +41% interview lift
Without
With
+40.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
51 currently pending
Career history
888
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
45.4%
+5.4% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
22.6%
-17.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 807 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/02/2026 has been entered. Status of the Claims Claims 20, 24, 25 and 27-36 are pending in a response of 09/02/2026. Withdrawn rejections: Applicant's amendments and arguments filed 09/02/2025 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Any rejection and/or objection not specifically addressed below are herein withdrawn. The following rejection and/or objection are either reiterated or newly applied. They constitute the complete set of rejection and/or objection presently being applied to the instant application. Claim Objection Claim 20 is objected to a minor informality. Claim 20 recites “the mixture” in line 9 and 12, but which would be better to recite “the mixture of the antioxidant system”. And claim 20 recites “combining the mixture with the retinol mixture”, but which would be better to recite “combining the mixture with the retinol mixture to form the topical formulation”. Appropriate correction is respectfully requested. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 35-36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. MPEP § 2163.II.A.3.(B) states, “when filing an amendment an applicant should show support in the original disclosure for new or amended claims” and “[i]f the originally filed disclosure does not provide support for each claim limitation, or if an element which applicant describes as essential or critical is not claimed, a new or amended claim must be rejected under 35 U.S.C. 112(a), as lacking adequate written description”. According to MPEP § 2163.I.B, “While there is no in haec verba requirement, newly added claim limitations must be supported in the specification through express, implicit, or inherent disclosure” and “The fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc., 935 F.2d at 1563-64, 19 USPQ2d at 1117”. Claim 35 recites “the retinol mixture is mixed at a temperature of about 30C to 70C”, but the specification does not appear to support the limitation. The specification discloses that “the fifth mixture may be added to the fourth mixture to form a sixth mixture at a fourth temperature (e.g., about 30° C. to about 70° C)” (see e.g., [0260]-[0261] of instant publication), and however, the fifth mixture does not refer to the claimed retinol mixture comprising at least retinol, isopentyl diol and dimethyl isosorbide. Claim 36 recites “further comprising adding bakuchiol after the combining the mixture with the retinol mixture”, and but the specification does not appear to support that limitation. The instant publication discloses the formulations further include bakuchiol (e.g., [0067], [0069] and [0072]), and however, the specification remains silent about when the bakuchiol is added. [0262] of instant publication discloses “bakuchiol is added into the six mixture,” and however, the six mixture is not the same as the retinol mixture containing at least isopentyl diol, dimethyl isosorbide and retinol. If applicant disagrees, please provide the location of the specification along with a reasonable explanation. Claims 20, 24, 25 and 27-36 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Method claim 20 recites “forming a mixture of an antioxidant … and an activation solvent system comprising isopentyldiol, ethoxydiglycol, dimethyl isosorbide, and a non-ionic surfactant”. However, the method does not require step of adding or mixing “ethoxydiglycol”. It is not clear when the ethoxydiglycol is added in this preparation process. Thus, claim 20 omits essential step of adding or mixing step of ethoxydiglycol. Each of claims 29 and 33 recites additional step using “further comprising”. However, it is unclear as to the timing of each adding step required to form the second mixture and the fourth mixture, respectively. Please note that method inventions should be carried out in a timely manner to establish a clear concept and reduction to practice. Further, dependent claim 29 recites “adding a first amount of dimethyl isosorbide to the first mixture”. Base claim 20 already combines retinol with “dimethyl isosorbide” to form a retinol mixture. It appears that the “first amount of dimethyl isosorbide” in claim 29 conflicts with the dimethyl isosorbide in claim 20. Clarification is requested. The remaining claims are also rejected due to the rejection of base claim 1. Conclusion The instant case is not in condition for allowance. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYUNG S CHANG whose telephone number is (571)270-1392. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Yong (Brian-Yong) S Kwon can be reached at 571-272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KYUNG S CHANG/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Show 2 earlier events
Jul 30, 2025
Non-Final Rejection mailed — §112
Oct 29, 2025
Response Filed
Jan 05, 2026
Final Rejection mailed — §112
Mar 05, 2026
Response after Non-Final Action
Jul 02, 2026
Notice of Allowance
Sep 02, 2026
Request for Continued Examination
Sep 04, 2026
Response after Non-Final Action
Oct 01, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778894
TABLET COMPRISING A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
2y 9m to grant Granted Nov 03, 2026
Patent 12773424
METERED DOSE FOR DEMODEX AND DISORDERS RELATED THERETO
4y 5m to grant Granted Oct 27, 2026
Patent 12773417
DILUTABLE FORMULATIONS OF CANNABINOIDS AND PROCESSES FOR THEIR PREPARATION
3y 0m to grant Granted Oct 27, 2026
Patent 12746188
HYDROGEL PATCH INCLUDING ADDITIVE SOLUTION ADJUSTABLE FOR ITS SYNERESIS PATTERN AND METHOD OF MANUFACTURING THE COMPOSITION
2y 0m to grant Granted Sep 29, 2026
Patent 12721935
ROBUST NITRIC OXIDE-RELEASING POLYMERS AND ARTICLES AND METHODS OF MAKING AND USES THEREOF
5y 7m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+40.8%)
2y 8m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 807 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month